Featuring Expert Speakers

Orphan Drugs & Rare Diseases Global Congress 2021 Europe

Lesha D. Shah, MD

Assistant Professor of Psychiatry, Medical Director, Child, Adolescent and Family Services, Icahn School of Medicine, Mount Sinai

Awaiting For photo & Bio

Senior Representative

Awaiting For photo & Bio

Senior Representative

Scroll to Top

Helena Baker RGN

CEO, Rare Disease Nurse Network

Helena trained as a nurse and specialised in theatres and anaesthetics. She became the first-ever anaesthetic nurse at the Royal London Hospital, supporting some of the most seriously injured patients in the south of England, as part of the Helicopter Emergency Medical Service.

Helena then moved into the pharmaceutical industry in sales and product management, working across Europe in pharmaceuticals and medical devices. Clinically, Helena worked in urology and oncology and then moved to the Medical Research Network.

As one of the founders, Helena fulfilled several roles, including Director of Nursing and Global VP for Operations & Nursing.

Helena was born with a rare disease called Fibular Hemimelia and spent most of her early years in hospital. 4 years ago she had her right leg amputated, but has rehabilitated ridiculously well and has since done 2 parachute jumps, walked miles, and has recently taken up canoeing.

Helena joined the Rare Disease Nurse Network at its formation in 2018 and is now interim CEO of the charitable organisation. Passionate about improving access to specialist care in rare diseases, she aims to enable healthcare professionals to reach the expert advice and knowledge to help them improve care. 

Lindsay Weaver

Co-Founder & CEO, Realise Advocacy, Trustee, Medics 4 Rare Diseases

Lindsay is the former CEO of MSUK where she served for 6 years and is a trustee at Medics 4 Rare Diseases. Lindsay also served as NHS England Metabolic Clinical Reference Group Patient and Public Voice member for over 4 years. During her time working in rare diseases, she has developed knowledge of the challenges that all stakeholders face in participating in NICE and NHS England access processes for new treatments.

Lindsay has become a strong advocate for supporting patient groups in access and has seen first-hand that well-supported patient advocates can have an impact on decision-making.

Philippa Norman

Projects Coordinator, Findacure

Philippa is the Projects Coordinator at Findacure. She is responsible for the coordination and delivery of major elements of Findacure’s Patient Group training projects. This includes leading the delivery of Findacure’s webinar programme, responsibility for a cohort of patient group mentees, supporting the Head of Operations in delivering the flagship workshop programme, and the launch of the new online Resource Hub. Philippa has worked directly with over 60 patient group leaders and advocates since joining the organisation and has gained insight into the needs of patients and the demands of patient group leaders. She is determined to see a world in which everyone cares about the stories and needs of the rare community and patient groups are a central cog and valued voice in the development of treatments.

Tom Pulles, MD

Vice President, Head of Medical Affairs & Patient Advocacy, Ultragenyx Europe

Tom has almost 20 years of experience in the Pharmaceutical and Biotech Industry. After obtaining his medical degree from Utrecht University in the Netherlands he worked as a physician in the Royal Netherlands Navy, followed by several local, regional, and global leadership functions in Medical Affairs and Patient Advocacy.

He lives in Switzerland with his family since 2011 and has dedicated his professional life to Rare Diseases in the past decade. In his current role at Ultragenyx as Head of Medical Affairs & Patient Advocacy, EMEA he supports bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

Angela Columbano

Head Business Development and Partnership, Genethon

Angela Columbano has over 20-year experience in the pharmaceutical and Biomedical industry.

Prior to Genethon, Angela was Principal at Sanofi Sunrise an early investment and partnering vehicle. Angela has also held various positions with Sanofi in Marketing and Business Development and Licensing for a number of therapeutic areas such as neuro-degeneration, age-related muscular diseases, cardiovascular disease and diabetes.

In the early years of her career, Angela was a Research Scientist with positions at Pfizer in Oncology and SmithKline Beecham. She obtained her PhD in Pharmaceutical Sciences at the School of Pharmacy of London and an MBA from Kingston University, UK.

Didier Caizergues

Head, Regulatory Affairs Department, GENETHON

A Doctor in Pharmacy, who holds a degree in Health law. He enjoyed a long career in the field of Regulatory Affairs.


He began his career as a consultant with International Drug Development (IDD), but soon joined the company SYNTHELABO in its Research and Development center where he worked for nine years. In this office Dr Didier CAIZERGUES oversaw the registration of new molecules that had evolved from cardiovascular, urological and anti‐depressive research.

He later headed up the international registration department for the Pierre Fabre group and for the next six years he practices to the fields of anti‐cancer drugs, anti‐depressants and orphan diseases. In 2001 he joined the GENETHON as Director of International Regulatory Affairs where he set up a regulatory affairs department specialized in gene and cell therapies in the fields of rare diseases. He obtained several clinical trials authorization in European countries and US for gene therapy products with lentivirus and AAV in the fields of muscular dystrophies and paediatric immunodeficiencies. He also manages scientific advice with the European Medicines Agency. He is also in charge of the assessment of new molecules or molecules already marketed still in the field of rare diseases in different working groups in European projects (Treat‐NMD).

Keith White

Head, Global Market Access, Amylyx Pharmaceuticals

Keith has over 20yrs industry experience in commercial and market access. He brings a very successful track record of developing and executing numerous speciality orphan launches. Keith started his career in sales at Merck, then spent 14yrs. at Genentech where he held leadership roles in sales, marketing, government affairs and market access. Keith then went on to head up the market access and pricing functions at Thrombogenics, Intermune, Intercept and Corbus Pharmaceuticals. Keith currently is the Global Head, Market Access and Pricing at Amylyx Pharmaceuticals. Keith holds a BA in Business and Economics from Lycoming College and an MBA in Marketing from Syracuse University.

Emily Crossley

Co-founder and joint CEO, Duchenne UK

Emily set up the Duchenne Children’s Trust in 2012 after her son was diagnosed with Duchenne. Before that she was a reporter and anchor for Channel 4 News and CNN International. The Duchenne Children’s Trust raised £3.5million in its first three years, to spend on clinical trials, research, and clinical trial infrastructure. The charity set up the annual Duchenne Dash, which brings in money for research and raises awareness around Duchenne muscular dystrophy. Emily has advocated on behalf of patients around the world. She’s spoken many times in the Houses of Parliament. She is a member of the MHRA patient group consultative forum.

Robert Donnell

Head of Business Development at Durbin PLC

Robert Donnell has 20 years’ experience in the pharmaceutical sector, working for large blue-chip companies such as Procter & Gamble and AstraZeneca.Robert joined Durbin, one of the world’s leading specialist Comparator and Clinical Trials Supply companies in 2009. He is responsible for global business development across the Durbin Group, including developing relationships and devising strategic partnerships with multinational pharmaceutical and biotechnology companies.Robert has advised several UK Members of Parliament on Healthcare policy and lectures extensively on Global supply issues.

Gergana Zlateva

VP & Business Unit Lead, Oncology, Patient & Health Impact, Pfizer

Available Shortly. 

Martin Zimmermann

Global Head of Regulatory Affairs, Alexion Pharma GmbH

Coming Soon. 

Josie Godfrey

Director, JG Zebra Consulting, Project Director, Duchenne UK's Project Hercules

Josie Godfrey is the Director of JG Zebra Consulting. Josie is Strategic Director for Duchenne UK’s ground-breaking multi stakeholder collaboration, Project HERCULES. She is a member of the International Rare Disease Research Consortium (IRDiRC) Working Group 3 looking at methodologies for assessing treatments for rare diseases and has acted as co-Chair of the EUCOPE Gene and Cell Therapy Working Group. Josie is a trustee of Metabolic Support UK. Josie has 10 years of experience working in rare diseases with a particular focus on HTA, market access and policy and public affairs. Josie set up and ran the NICE Highly Specialised Technologies programme as well as the predecessor programme, the Advisory Board for National Specialised Services (AGNSS).

Doug Danison

Head of Europe, bluebird bio

Doug Danison is the Head of Europe at bluebird bio since January 2021. He joined bluebird bio in July 2015 to establish the global pricing, market access, and health economics team known as Access Value & Evidence Strategy (AVES).

Doug has more than 20 years of Pricing & Market Access experience, including roles with Eli Lilly & Company, Amgen, Millennium/Takeda Oncology. In that time, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post-launch lifecycle management. While addressing market access challenges from a variety of vantage points including Global, European Regional, and U.S. roles he’s built teams, processes, and a knowledge base that enables the execution of market access strategies that anticipate and meet the needs of access decision-makers in an increasingly challenging market access environment.

Simu Thomas PhD

Vice President, Global Head HEOR, Alexion Pharmaceuticals

Available Shortly 

Femida Gwadry-Sridhar

CEO & Founder Pulse Infoframe Inc.

Dr. Femida Gwadry‐Sridhar is the Founder and CEO of Pulse Infoframe Inc. She has her PhD in Research Methodology, Health Economics, McMaster University. She is a pharmacist, epidemiologist and methodologist with over 25 years of experience in clinical trials, disease registries, knowledge translation, health analytics and clinical disease outcomes. She founded the first knowledge translation health informatics lab in North America in 2006, creating a collaborative ecosystem for interdisciplinary research. In 2008 this facility, I‐THINK research, developed a physical and virtual platform to support multidisciplinary research. The platform has evolved to enable the integration of clinical, imaging and histopathology data.

 

Pulse Infoframe has developed healthieTM, a revolutionary evidence-based platform transforming rare disease and cancer clinical research and treatment. Pulse’s SaaS data platform is becoming the de facto standard for real work evidence, meeting an urgent regulatory requirement. Pulse builds multi-stakeholder collaborative networks of pharmaceutical companies, researchers and patients and enables stakeholder access to clinical trials, input on trial design, new treatment development, and accelerated research. Pulse captures, organizes, analyzes, curates and shares existing and unique data using its industry leading and scalable data-sharing platform powered by AI and machine learning.

 

Under Dr. Gwadry-Sridhar’s guidance Pulse has developed a global presence.  Pulse has collaborated with international funding agencies advancing the requirements for rare disease registries. Collecting relevant and actionable data in rare disease is essential.  Pulse has addressed relevant questions about data sharing, governance, ontologies and patient reported outcomes- all key to understanding and enabling the development of real-world evidence. DrGwadry-Sridhar is a life-long collaborator and has done so across different disciplines and cultures. This experience has resulted in a comprehensive understanding of the value of collaboration to fast-forward progress and improve lives everywhere.

Ryotaro Ishikawa

Global Market Access Director, Novartis

Coming Soon! 

Martina Garau

Director, Office of Health Economics

Coming Soon! 

Saira A. Jan

VP & Chief Pharmacy Officer, Horizon Blue Cross Blue Shield of New Jersey

Dr Saira Jan is the Vice President and Chief Pharmacy Officer at Horizon Blue Cross Blue Shield of New Jersey and Professor Emerita at the Rutgers State University of New Jersey. With a passion for creating positive patient outcomes, driving innovation, and improving healthcare delivery, Dr Jan oversees Horizon’s pharmacy and medical integration initiatives for Commercial, Medicaid, and Medicare lines of business. She has over 25 years of experience in health care management, research, and academics, and during that time, she has worked closely with business units, clinical quality groups, and medical management teams to deliver integrated and comprehensive services for over 3.5 million lives.

 

Saira leads and established one of the first managed care curriculums and Managed Care Residency at Rutgers, one of the first programs in the US. She has extensive experience in outcome-based research projects with Harvard University and numerous other nationally acclaimed institutions. Dr Jan has also lead the opioid peer to peer collaboration model in New Jersey and has overseen the development of The Rutgers Opioid Toolkit, childhood obesity, adherence, diabetes and various other and community outreach program, involving Rutgers pharmacy students and Horizon clinical staff. Saira also works extensively with the National Blue Cross Blue Shield Association, CMS, FDA, as well as international healthcare groups on various programs and initiatives.

Dr. Jan has a Masters in Pharmacology from St John’s University and a doctorate in Pharmacy from Rutgers University.

Lesha D. Shah, MD

Assistant Professor of Psychiatry, Medical Director, Child, Adolescent and Family Services, Icahn School of Medicine, Mount Sinai

Lesha D. Shah, M.D. is Assistant Professor of Psychiatry and the Medical Director of Child, Adolescent and Family Services at the Icahn School of Medicine at Mount Sinai. Her primary academic focus is pediatric research ethics and physician perspectives around medical decision-making for children. She studies issues of consent and capacity as they interface with family complexity and innovative medicine with a focus on gene therapy clinical trials. She co-chairs the Pediatric Gene Therapy and Medical Ethics Working Group (PGTME), whose mission is to advance research, education, and policy in addressing emergent ethical issues around investigational gene therapy in pediatric populations. Dr. Shah serves on the Icahn School of Medicine at Mount Sinai Institutional Review Board and has published on issues related to medical ethics in Pediatrics, the Journal of the American Academy of Child and Adolescent Psychiatry, and the American Journal of Bioethics. She is dually board certified by the American Board of Psychiatry and Neurology.

Awaiting for Photo & Bio 

Available Shortly. 

Reserved 

Paul Greenland,

President EMEA, Amryt Pharma

Paul joined Amryt Pharma as President EMEA Region in September 2019 and brings over 30 years of experience across a broad range of International commercial roles in the pharmaceutical industry. Mr Greenland joined Amryt through the acquisition of Aegerion Pharmaceuticals where he held the position of President EMEA Region and had directed the launch and subsequent growth of Myalepta (metreleptin), a treatment for patients with Lipodystrophy. Prior to this Mr Greenland was Vice President of Biologics at Hospira where he directed the establish their fledgling commercial biosimilar business in Europe.

Pedro Franco

Director for Global Regulatory & Scientific Policy (GRASP), Merck

Pedro Franco holds a degree in Pharmacy (PharmD) from the University of Lisbon, a Master in Organic Chemistry (M.Sc) from the New University of Lisbon with collaboration with Imperial College in London, and a Ph.D. in Orphan drugs and Rare diseases from the University of Sheffield. Pedro Franco completed also his music studies (Cello) in Lisbon.

Currently, Pedro is working as a Director for Global Regulatory & Scientific Policy (GRASP) at Merck, and he is mainly focused on regulatory intelligence, strategy, and policy. In addition, he is the liaison for the China and Latam region concerning regulatory and policy topics. Previously, He worked at the European Medicines Agency for 12 years in different roles and departments mainly focusing on regulatory affairs, international collaboration, assessment, authorisation of medicines, orphan drugs, paediatrics, peer review, quality, and strategy. Beforehand, he was working at INFARMED (the Portuguese national competent authority) as a pharmaceutical assessor. Before joining regulatory competent authorities, he worked as a post-graduate research fellow in the area of toxicology, carcinogenic chemistry, and drug development.

Kerry Leeson-Beevers

National Development Manager & Project Lead, Alström Syndrome

I joined Alström Syndrome UK (ASUK) in 2004 when my son was diagnosed with the condition. ASUK is a patient organisation supporting families who have a diagnosis of this ultra-rare and complex genetic condition. I am the National Development Manager, responsible for overseeing the Family Support Service and I work closely with our medical teams in Birmingham as we work in partnership to deliver NHS highly specialised multi-disciplinary clinics. I also manage ASUK’s contracts with pharmaceutical companies to support clinical trials.

 

I am the Project Lead for ‘Breaking Down Barriers’ and I work with patient organisations and support groups throughout the UK to develop supportive and inclusive services for individuals and families affected by genetic disorders.

 

I have been involved in various UK, EU and global projects focussing on patient engagement in clinical trial designs and drug development. I am a member of the CIOMS XI working group developing guidelines on patient involvement in the development and safe use of medicines and I am a member of the Patient Safety Communication Advisory Panel for Bayer.

 

I am a patient representative on the UK Rare Disease Policy Board, overseeing the implementation of the UK Strategy for Rare Diseases and I am Co-Chair of the Patient and Public Involvement Advisory Group for the CONCORD Study looking at the coordination of care for rare disease patients, funded by the National Institute for Health Research.

Awaiting for photo and bio

Senior representative 4

will be available shortly. 

Awaiting for photo and bio.

Senior Represntative 3

Available shortly

Awaiting for photo & bio

Senior Representative 2

Available Shortly, 

Paolo Morgese

EU Director Market Access, Alliance for Regenerative Medicine

Paolo is a healthcare investment and market access professional with more than 15 years of experience in both assessing and supporting access to innovative healthcare technologies. Paolo is currently VP Market Access at Alira Health a healthcare advisory company and EU Director Market Access and Member Relations at the Alliance for Regenerative Medicine (ARM). Between 2012 and 2017 he worked at Deerfield Management, a healthcare investment company, where he was Director of EU Research and Market Access. Prior to that, he worked at Merck Serono for five years, Kyphon, which became Medtronic, and also spent several years with the Italian HTA Agency Agenas. Paolo’s interests and expertise are centered around healthcare technology value assessment and maximization, with a particular interest in the early stages of product development.

Rhian Kiely

RWE Commercial Director, Europe Open Health Evidence & Access

Rhian has experience in the planning and execution of real-world evidence projects in order to generate impactful evidence to drive change. She has experience in developing strategic evidence generation plans both at the local and global level to support clients to navigate the launch of their product and beyond. Rhian also supports the OPEN Health evidence teams in the delivery of projects to generate evidence and support its dissemination. Rhian has a degree in Applied Biology from Cardiff University and a DPhil in Clinical Medicine from Oxford University. Rhian’s doctoral research focussed on DNA repair, in particular the cellular response to chemotherapy. Rhian has published her work in several peer-reviewed journals and has presented her work at national and international conferences. Rhian has led the feasibility exercise that OPEN Health has recently completed with Apellis, provide consulting support and project management to the project. Rhian also drafted the Project Concept for the GALTOS study and would be delighted to use her experience to support the delivery of this study.

Dr. Linda Popplewell

Department of Biological Sciences, Royal Holloway University of London

Expertise lies in the development of pre-clinical gene therapies for neuromuscular diseases, in particular muscular dystrophies based on gene addition, endonuclease-mediated gene editing, antisense oligonucleotide (AO)-induced exon skipping and gene silencing. Having performed well in clinical trial, FDA approval is currently being sought for a patented AO developed in the Popplewell lab for a particular subset of Duchenne muscular dystrophy (DMD) patients. Dr Popplewell is PI of an upcoming clinical trial of an optimised microdystrophin AAV, which would have universal DMD patient applicability. She is an elected board member of the BSGCT, sits on the Management Committee of an eCOST Action and is an invited member of the MDEX Consortium.

Pedro Franco

Director for Global Regulatory & Scientific Policy (GRASP), Merck

Pedro Franco holds a degree in Pharmacy (PharmD) from the University of Lisbon, a Master in Organic Chemistry (M.Sc) from the New University of Lisbon with collaboration with Imperial College in London, and a Ph.D. in Orphan drugs and Rare diseases from the University of Sheffield. Pedro Franco completed also his music studies (Cello) in Lisbon.

Currently, Pedro is working as a Director for Global Regulatory & Scientific Policy (GRASP) at Merck, and he is mainly focused on regulatory intelligence, strategy, and policy. In addition, he is the liaison for the China and Latam region concerning regulatory and policy topics. Previously, He worked at the European Medicines Agency for 12 years in different roles and departments mainly focusing on regulatory affairs, international collaboration, assessment, authorisation of medicines, orphan drugs, paediatrics, peer review, quality, and strategy. Beforehand, he was working at INFARMED (the Portuguese national competent authority) as a pharmaceutical assessor. Before joining regulatory competent authorities, he worked as a post-graduate research fellow in the area of toxicology, carcinogenic chemistry, and drug development.

Dr. Nicolas Sireau

CEO and Chair of Trustees, AKU Society

Dr Nicolas Sireau is the CEO and Chair of Trustees at the AKU Society, a patient group that helps people with AKU (short for alkaptonuria), a rare genetic disease affecting both his children. He is also co-founder and Chair of Findacure, an organisation that helps rare disease patient groups. Previously, Nick was the CEO of SolarAid, an NGO working in Africa. He is a fellow of the Ashoka Fellowship of Social Entrepreneurs and has a PhD in the social psychology of social movements. He is the editor of ‘Rare Diseases: Challenges and Opportunities for Social Entrepreneurs’ (Greenleaf 2013) and of the ‘Patient Group Handbook: A Practical Guide for Research and Drug Development’ (Findacure 2016).

Dr. Cesare Spadoni

Founder & COO, Oncoheroes Biosciences

Cesare is Co-founder and Chief Operating Officer of Oncoheroes Biosciences Inc. and he has more than 20 years of experience in the drug development field, in both scientific and commercial roles. Previously, he held senior positions at AMRI, Aptuit Laurus, ThalesNano and Auxiliis BV. Cesare started his career as research scientist in a pharmaceutical company (Eisai, London) and in academia (Institute of Enzymology, Budapest).

 

Following the death of his first daughter Laura to cancer, Cesare set up aPODD Foundation, a London-based charity focused on accelerating paediatric oncology drug development. As aPODD’s chairman and trustee he is actively involved on a pro-bono basis in drug repurposing projects, advocacy efforts and research collaborations with other childhood cancer charities.

 

Cesare holds an MSc in Applied Molecular Biology and a PhD in Neurosciences from UCL, University of London, as well as an MBA from the Central European University, Budapest.

Helen Springford

Chief Operating Officer, Illingworth Research Group

Helen Springford has over 28 years’ experience in the Clinical Trials arena. Having worked as a nurse in cardiac transplantation in the UK and Australia, Helen moved into clinical research in 1992, initially as a research nurse. Since then, she has managed an SMO and held various positions in both CROs and big pharma within several functional areas including Clinical Operations, Project Management, Business Development and Proposals. Helen was appointed Vice President, Strategic Development at Illingworth Research in August 2016 and was promoted to Chief Operating Officer in April 2019. Helen has always promoted the patient as an active participant in their care and has brought this to the current role where patient focused solutions such as mobile research nursing allows people, irrespective of their geography or state of health to participate in clinical trials. Patient empowerment, whether adult or child is an important part of Helen’s work and has been something of personal interest throughout her career.

Awaiting for phpto & bio

Senior Representative

Available Shortly 

Awaiting for photo & Bio

Senior Representative

Available Shortly

Rafał Świerzewski

President of Board, Fundation for Patients with Rare Diseases COCARDA

Rafal Swierzewski has been involved in patient advocacy for ten years as both a scientist and rare cancer survivor. He earned his PhD in 2006 in chemistry by examining physical and chemical properties of model macromolecules (incl. new chemotherapy compounds) in cellular environment. From 2013 to 2016 he served as Board Member of the European Cancer Patient Coalition (ECPC). Currently, he continue his activity, representing ECPC in Patients’ and Consumers’ Working Party within the European Medicines Agency (EMA). Through the EMA, he is involved in various projects, such as Adaptive Pathways, IMI-ADVANCE (Scientific Advisory Board member) and IMI-WEBRADR. Rafal also represents patients’ interests in the Stakeholders Group for European Union’s clinical trial portal and database, created by EMA to construct new system for implementing European regulations on clinical trials and clinical data. Rafal is also a member of Technical Anonymization Group (TAG) of the EMA, which continue the work undertaken during the development and finalisation of the external guidance on the anonymization of clinical reports for publication. From March 2018 he is President of the Board of Foundation for Patients with Rare Diseases “COCARDA”, an innovative patients’ driven research organization established in Poland.

Emily Crossley

Co-founder, Duchenne UK

Emily Crossley is the co-founder and joint CEO of Duchenne UK. She graduated from Oxford University with a degree in modern history and became a reporter and anchor for Channel 4 News and CNN International. After her eldest son was diagnosed with Duchenne Muscular Dystrophy (DMD), she set up the Duchenne Children’s Trust. The charity joined forces with Joining Jack and is now Duchenne UK. In 7 years Duchenne UK has committed £14 million to funding treatments and a cure for DMD. Emily helped to create the Duchenne Dash, an iconic 24-hour bike ride from London to Paris to raise money and awareness for DMD. This year the Duchenne Dash raised over £1.2 million. Emily has advocated on behalf of patients around the world. She has represented the patient community in meetings at the EMA, the MHRA, the FDA, and NICE. She has spoken at Parliamentary meetings and was praised in the House of Commons for the charity’s work, by the Minister for Life Sciences, George Freeman MP. She is a member of the MHRA patient group consultative forum.

Femida Gwadry-Sridhar,

CEO and Founder, Pulse Infoframe Inc.

Femida is a pharmacist, clinical epidemiologist, and methodologist with over 25 years of experience in clinical trials, patient registries, knowledge translation, health analytics, and clinical disease outcomes. Femida has received more than $10 million in research funding as a principal investigator or co-investigator. She was awarded a career scientist award in 2006 from the Canadian Institute of Health Research and through her work founded the first knowledge translation health informatics lab in North America, creating a collaborative ecosystem for interdisciplinary research. Recently recognized as a lifetime fellow of CIHR for her contributions to global research with impact.

Femida has published over 200 manuscripts and abstracts in top tier journals and actively continues her professional interests in enabling technologies for better provider workflow and patient engagement. Femida is a founding member of the International Society for Pharmacoeconomics and Outcomes Research medication adherence group, which has provided an early glimpse into how to conduct research in adherence.

She is an expert reviewer in North America and Europe on large scale research network grants and a frequent international speaker on patient engagement, patient registries, innovation, health informatics and data visualization. The recipient of numerous nominations, awards and positive press, Femida has joined Springboard Enterprises as a female entrepreneur in digital health. She also holds her Ph.D. in research methodology and health economics from McMaster University.

Dr David A Walker

B Med Sci FRCP FRCPCH, Professor of Paediatric Oncology, Children’s Brain Tumour Research Centre

David was born in Scotland and qualified in Medicine from University of Nottingham in 1977 subsequently training in adult and paediatric medicine in UK (Cambridge, St Mary’s Paddington, Leicester, Sheffield, Great Ormond Street Hospital and Royal Children’s Hospital, Melbourne Australia), being appointed as a Senior Lecturer in Paediatric Haematology and Oncology in Nottingham in 1990 and appointed as Professor in 2005.

He led the children’s brain tumour trials’ committees in UK (CCLG 92-97) and Europe (SIOPe 97-2001) and co-chaired the International Consortium of Childhood Low Grade Glioma 1997 – 2014. He co-chaired the Royal College of Paediatrics and Child Health (RCPCH), Society of British Neurological Surgeons (SBNS)and Royal College of Nursing (RCN) working party to establish a network of children’s brain tumour treatment centres across the UK reporting in 1997. He helped to develop the Children’s Brain Tumour Research Centre at the University of Nottingham http://www.cbtrc.org/. It celebrated its 20th anniversary in 2017. He helped initiate the Teenage Cancer Trust (TCT) adolescent units in East Midlands Children and Young People’s Cancer Service (EMCYPICS) and was a TCT Visiting Professor to Royal Children’s Hospital in Melbourne, Australia in 2007.